Parabilis Medicines, Inc. (NASDAQ:PBLS) Receives $41.67 Consensus Target Price from Analysts

Parabilis Medicines, Inc. (NASDAQ:PBLS) has received an average recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $41.6667.

Several analysts have weighed in on the company. Evercore assumed coverage on Parabilis Medicines in a research note on Monday, July 6th. They set an “outperform” rating on the stock. Guggenheim initiated coverage on Parabilis Medicines in a report on Monday, July 6th. They set a “buy” rating and a $40.00 target price for the company. Zacks Research upgraded Parabilis Medicines to a “hold” rating in a research report on Tuesday, July 7th. Leerink Partners began coverage on shares of Parabilis Medicines in a research report on Monday, July 6th. They set an “outperform” rating and a $40.00 price target for the company. Finally, Lifesci Capital upgraded shares of Parabilis Medicines to a “strong-buy” rating in a research note on Monday, July 6th.

Parabilis Medicines Stock Performance

NASDAQ PBLS opened at $34.90 on Friday. The firm has a fifty day moving average price of $29.73. Parabilis Medicines has a 1 year low of $24.51 and a 1 year high of $36.82.

Insider Buying and Selling at Parabilis Medicines

In related news, Director Alan Sebulsky purchased 9,065 shares of the business’s stock in a transaction on Monday, June 15th. The shares were bought at an average cost of $26.49 per share, with a total value of $240,131.85. Following the transaction, the director owned 30,000 shares of the company’s stock, valued at approximately $794,700. This trade represents a 43.30% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Guy Levy acquired 500,000 shares of Parabilis Medicines stock in a transaction on Thursday, June 11th. The shares were bought at an average price of $20.00 per share, with a total value of $10,000,000.00. Following the purchase, the insider directly owned 1,027,000 shares in the company, valued at approximately $20,540,000. The trade was a 94.88% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders acquired 530,000 shares of company stock worth $10,723,528.

Parabilis Medicines, Inc is a healthcare company in the Biotechnology industry.